Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of […]

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.

Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.

At a glance

Company: Quantum BioPharma Ltd.
Ticker: NASDAQ: QNTM, CSE: QNTM
Announcement: Product

Key figures

Estimated people living with MS worldwide: 2.9 million
Estimated people with MS in the United States: about one million
Most common diagnosis age range: 20 and 50
Mean age at diagnosis globally: 32
Female rate compared with male rate: roughly twice

Products and programs

Lucid-MS
unbuzzd

Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of…

Questions around this news

What is Lucid-MS, and what is its role in Quantum BioPharma’s MS work?
The release describes Lucid-MS as a patented new chemical entity and says it takes a fundamentally different approach from existing therapies. It is the company’s focus in multiple sclerosis, and its phase 2 development is supported by an ongoing imaging collaboration with Massachusetts General Hospital.
What is the purpose of the imaging collaboration mentioned in the release?
The release says Quantum BioPharma has an ongoing imaging collaboration with Massachusetts General Hospital in support of Lucid-MS’s phase 2 development. It does not provide further details about the imaging methods or the collaboration’s specific activities. The partnership is presented in the context of the company’s multiple sclerosis research.
What does phase 2 mean in drug development?
Phase 2 is a stage of clinical testing that generally evaluates a potential medicine in people who have the condition it is intended to address. Studies at this stage commonly examine safety and whether the treatment shows signs of benefit, while helping researchers determine how to design later studies.

SEC filings

SCHEDULE 13GSCHEDULE 13G Filed July 8, 2026

Earlier from Quantum BioPharma Ltd.

Back to News Center